Review on Novel Anticancer Agent of Dostarlimab

S. Naveenkumar [1], N. Ramanathan[2]
[1, 2] Dept of Pharmaceutical Chemistry
[1, 2] Pallavan Pharmacy College. Kanchipuram.631 502.

Abstract- *One of the most deadly illnesses of the 20th century, cancer has alarmingly increased in the 21st, to the point where it now affects every 4 people. Accordimg to GLOBOCAN 2020, there were 19 million new cases of malignancy and roughly 10 million cancer related deaths globally in 2020. The highest incidence rates are for breast cancer (11.7%), followed by lung cancer (11.4%) and colorectal cancers (10%). Lung cancers (18%) lead the list in terms of mortality, while colorectal (9.4%) and liver (8.3%) cancers affect both sexes at all ages. Dostarlimab is a novel medication with an action mechanism similar to other PD-1/PD-L1 inhibitors that was previously used to treat endometrial malignancies. Many malignancies, including as pancreatic, ovarian, fallopian tube, non-small cell lung cancer and small cell lung cancer can be treated with this medication in the future.*

Keywords- Dostarliamab, Malignancy, Colorectal cancer, Endometrial cancer,Immunotherapy, T-Cells, PD-1/PD-L1 inhibitors, Combination therapy.

I. INTRODUCTION

Despite years of research in this area cancer is still major health issue over 10 million deaths annually. Its still one of the deadliest diseases that immunity has ever experienced. Numerous therapeutic modalities have been implemented, such as a medications assisted chemotherapy, radiation therapy, immunotherapy, and surgery. The newest area of study in this subject is immuno-oncology, whose potential and extent have yet been fully determined. Certain immune system components are employed in immunotherapy to treat a variety of illnesses, notably solid tumours and cancer. The goal of cancer immunotherapy is to stimulate the immune system again, which tumot cells have done in a number of ways. Numerous innovative immunotherapy approaches are being explored to treat cancer or reduce the cytotoxic side effects that come with certain cancer treatments. Immunotherpies have a relatively narrow scope and they target malignant stem cells as well as metastatic tumour when triggered, which in this emphasis that capacity to access even the smallest tumors where surgeons might not be able. Additiionally, Immunotherapy has focused attention on the creation of cancer vaccines which `to completely eradicate it in its entirety. In addition, a number of cancer treatments use antibody-based medications, therapy that has a direct or indirect connection to immunotherapy.[1]

Dostarlimab, a humanized monoclonal antibody of the IgG4 isotype, is manufactured using recombinant DNA technology in mammalian Chinese hamster ovary(CHO) cells. Its binds to PD-1 on T cells and prevents interactions with its ligands, PD-L1 and PD-2, which trigger immunological reactions. The immunotherapeutic drug dostarlimab during cancer treatments, approach that supports the body natural anti-tumor immune response. Each heavy chain of the antibody has a serine to proline substitution (S228P) to encourage the stability of disulfide connections between the two heavy chains, preventing the creation of half-antibodies. PD-1 is a inhibitory immunological checkpoint receptor in relation to activated T cells. By interacting with its ligands, programmed cell death ligands 1 and 2 (PD-1 and PD-2),PD-1 decrease activated effector T-cell capabilities such as proliferation cytokine production and cytotoxic action. Due to competitive environment of anti-PD-1 antibodies, patients with cancer can select from a range of dosing regimens, disease specific treatments, tolerance profiles, and cost effective options. [2]

DOSTARLIMAB WITH MECHANISM OF ACTION:

A genetic defect known as mjsmatch repair deficiency (MMRd) prevents errors from being corrected during DNA replication. CRCs are where MMRd is most commonly observed. T-cells also express Programmed Death 1 (PD-1), a critical immunological checkpoint receptor that is essential for the immunosuppression unique to malignant cells. It has been discovered that CRCs with MMRd are susceptible to antibody mediated PD-1 immune checkpoint receptor blockage. Therefore, to prevent or kill T-cell PD-1 Receptors, programmed death 1 (PD-L1) attaches to them, preventing immunosuppression. [3,4,5,6]

ENDOMETRIAL CANCER :

The tumor form known as endometrial cancer is linked to elevated incidences of DNA mismatch repair deficiency and microsatelliate instability high condition (MSI-H/dMMR). Endometrial cancer was shown to be among the malignancies with the greatest rate of MSI-H/dMMR (about

30%), depending by Endometrial cancer histologic type and tumor grade. This information was based on an evaluation of 12,019 tumor samples, representing 32 different tumor types, by 2017 [Le et al]. These outcomes supported preliminary findings from the Cancer Genome Atlas Research Network, which showed that 34% of Endometrial cancer cases and 40% of tumors with endometriallll histololgic features were classified as MSI-H. Nlne there publications that indicate MSI-H/dMMR Endometrial Cancer is just type I (endometrial hisotologic features), despite the fact that other reports, type Ⅱ Endometrial cancer can also be MSI-H/dMMR particularly in cases with (serous and distinct cell histologic features). MSI-H/dMMR cancer are linked a to 100-1000 fold increase in mutation rates and exhibit significant levels of neoantigens due to their incapacity to repair DNA replication errors; hence, patients with these malignances are immunogenic. A population prepared to respond to anti-programmed death-1 (PD-1) and anti-programmed death-ligand-1 (PD-L1) agents may comprise MSI-H/dMMR cancers.[7]

COLORECTAL CANCER:

A little gather of colorectal patients (18 people) fair experienced something no brief of a logical marvel, their illness died down totally after test treatment conducted by a gather of specialists at Dedication Sloan Kettering Cancer Center, Unused York. The trial's result is being labeled as astounding since each understanding was cured totally without any special case. These groundbreaking comes about are unexpected in cancer inquire about concurring to a few specialists. These patients went through medicines like chemotherapy, radiation, and in a few cases, life-altering surgery that may modify bowel, urinary and sexual capacities. A clinical trial outlined by Dr. Diaz in 2017 worked as motivation for the think about. It included 86 people who had metastatic cancer that had spread all through their bodies. In any case, all of the tumors had a quality change that denied cells from repairing DNA harm. These changes are found in 4% of cancer patients. Dostarlimab, a Merck checkpoint inhibitor, was given to patients in that try for up to two a long time.

In around one-third to one-half of the patients, tumors contracted or stabilized, and they survived longer. Tumors killed in 10% of those who took portion within the study. The try must be copied in a much bigger ponder, concurring to the analysts, who point out that the current think about as it were looked at people with a interesting hereditary signature in their tumors. Be that as it may, they accept that observing total remission in 100% of the patients examined may be a exceedingly positive early sign.

LUNG CANCER:

Lung cancer is the most common cause of cancer death in men and women worldwide, with relatively poor survival outcomes, as evidenced by a 5-year survival rate of 21.1%. About 85% of lung cancer cases are non-small cell lung cancer (NSCLC). Although chemotherapy has historically been the primary treatment option for patients with advanced or relapsed NSCLC, the treatment paradigm has been revolutionized in recent years by the advent of immune checkpoint inhibitors (ICI). As a first-line treatment, ICI has become the standard of care, either as monotherapy in selected patients or in combination with chemotherapy.

Phase 2 results of the largest global trial of programmed death receptor (PD-1) inhibitors in patients with metastatic non-squamous non-small cell lung cancer (NSCLC). 8.8 months in patients receiving dostarlimab plus chemotherapy compared with 6.7 months in patients receivimg pembrolizumab and chemotherapy. The GSK study found that the objective response rate (ORR) was 46 percent in patients receiving dostarlimab plus chemotherapy compared with 37 percent in patients receiving pembrolizumab plus chemotherapy. The results of the primary analysis were presented at the 2022 European Society for Medical Oncology (ESMO) Immuno-Oncology Congress.

PANCEATIC CANCER:

The seventh leading cause of cancer-related death worldwide is pancreatic cancer (PC). A number of factors contribute to a poor prognosis for PC, including a diagnosis at an advanced stage, early distant metastases, and remarkable resistance to the majority of conventional treatments. The pathogenesis of PC is by all accounts altogether more muddled than initially expected, and discoveries in other strong growths can't be extrapolated to this danger. To foster viable therapy plans delaying patient endurance, a multidirectional approach including various parts of the disease is required. Specific headings have been laid out; be that as it may, further investigations uniting them all and interfacing the qualities of every treatment are required.

PARP inhibitors have monotherapy activity in BRCA1/2 mutant metastatic pancreatic cancer; however, several other genes and associated proteins exist in the homologous recombination repair (HRR) pathway that promotes resistance to chemotherapy and radiation injury. HRR-deficient tumors have a reduced self-repair capacity and are sensitive to PARP inhibition, but ionizing radiation can also induce DNA breaks.

Ongoing research suggests that PARP inhibitors may cause radiosensitivity and may also increase sensitivity to immunotherapy. We conducted a phase 2 study of niraparib and dostarlimab with radiation in a biomarker-unselected PDAC population, based on the immunomodulatory and radiosensitizing effects of PARP inhibitors.

CHEMOTHERAPY:

In cutting edge stage and high-risk endometrial disease, adjuvant treatment is the norm of care and for the most part incorporates chemotherapy regardless of radiotherapy. The best utilization of these 2 strategies together or independently is as yet the object of study. Besides, as per the most recent examination, synergistic utilization of chemotherapy and immunotherapy is a promising option for standard chemotherapy. In particular, dostarlimab in addition to carboplatin-paclitaxel essentially expanded movement free endurance among patients with essential high level or repetitive endometrial disease, with a solid advantage in the dMMR-MSI-H populace. In the stage 3, randomized, doubleblind, multicentre RUBY preliminary, patients were haphazardly designated in a 1:1 proportion to get dostarlimab (500 mg) or fake treatment intravenously, in mix with carboplatin at a region under the bend of 5 mg for every milliliter each moment,

Paclitaxel at a portion of 175 mg for each square meter of bodysurface region intravenously at regular intervals for the initial 6 cycles, trailed by dostarlimab (1,000 mg) or fake treatment intravenously like clockwork for as long as 3 years, or until infection movement, treatment end brought about by poisonous impacts, patient or specialist withdrawal, or passing. The most applicable endpoints were sans movement endurance as surveyed by the specialist as per Reaction Assessment Rules in Strong Cancers (RECIST), security and in general endurance. To contrast chemotherapy as a CarboplatinPaclitaxel and dostarlimab in the principal line, another clinical preliminary is in progress and will end in October 2029. The multicentre, open-name, randomized study is surveying the viability and wellbeing of dostarlimab versus carboplatinpaclitaxel in patients with MMR lacking backslide.

DIFFERENT CANCER IMMUNOTHERAPY STRATIGIES:

CHECKPOINT BLOCKADE:

The body's defenses against threats like cancer, bacterial infections, and viral infections are heavily reliant on the immune system. Antigen-presenting cells, which are specialized cells, are on the lookout for signs of potential danger throughout the body. They "present" this evidence to T cells, the immune system's active warriors, in the lymph nodes closest to them. Assuming the Lymphocytes perceive the danger, they become initiated, increase into a military, and go out to chase and kill undermining cells any place they are found. Insusceptible designated spots are the "brakes" of the safe framework

ONCOLYTIC VIRUS:

Safe cells called Immune system microorganisms can perceive and go after cells containing unfamiliar particles (like those from an infection) known as antigens. Likewise, malignant growth cells frequently make unusual particles, known as cancer antigens, albeit these frequently don't set off major areas of strength for a reaction.

When oncolytic infections contaminate and obliterate disease cells, flotsam and jetsam is delivered by the perishing cells. This garbage incorporates not just duplicates of the infection and viral antigens, yet additionally malignant growth cell trash containing cancer antigens and atoms that alert the invulnerable arrangement of harm. These particles draw in the consideration of antigen-introducing cells, which watch the body and get antigens as proof of a danger.

T-CELL THERAPY:

Immune system microorganism treatment is a possible therapy for malignant growth that involves the patient's own Lymphocytes as a "living medication". Lymphocytes are the cells of the resistant framework answerable for searching out and obliterating undesirable cells. These undesirable cells are normally cells contaminated with destructive microorganisms like microbes or infections, however some Lymphocytes can likewise normally perceive and kill malignant growth cells.

Different Immune system microorganism treatment procedures change in the wellspring of the Lymphocytes, how White blood cells are treated beyond the body, and the way that Lymphocytes perceive the phones they ought to kill whenever they are gotten back to the patient. Normally, an Immune system microorganism distinguishes an objective antigen by utilizing receptors on its surface, called White blood cell receptors. Hereditary designing permits specialists to change which specific antigen will be designated by an Immune system microorganism or change the way how Lymphocytes perceive target antigens.

ANTIBODY THERAPY:

Antibodies are a kind of particle that the human resistant framework uses to recognize and target things that don't have a place in the body, including microscopic organisms, infections, and malignant growth cells. The objectives of antibodies can be particles drifting openly in body liquids, particles on the outer layer of attacking infections or microbes, or atoms on the outer layer of a cell in the body. Antibodies can likewise exactly perceive atoms that separate disease cells from ordinary cells. By restricting to the malignant growth cells, antibodies might work alone or may assist the safe framework with battling the disease. For instance, in the event that an objective cell is bound to the arm of a neutralizer, and a resistant cell ties to the stem, then the safe cell can assault and obliterate the objective cell.

CELL-BASED IMMUNOTHERAPY:

Cell-based malignant growth immunotherapies are therapies that include conveying living safe cells into a patient to battle their disease. At times, the resistant cells are gathered from the patient and are an ideal hereditary match, while in different cases, they are gathered from a relative or other very much paired sound benefactor. Frequently, the living cells are enhanced for specific cell types as well as are changed in an examination research center or concentrated assembling office to boost their capacity to battle the disease before they are given to the patient.

***Natural killer (NK) Cell Therapy**;

Natural killer (NK) cells are a significant kind of insusceptible cell that flows all through the body. They perceive cells that seem contaminated, modified, harmed, or worried, and are promptly outfitted with the instruments to assault and kill such cells. NK cells are viewed as a piece of the natural resistant framework, which incorporates a considerable lot of the people on call for any strange cells or movement in the body, and rushes to answer any likely dangers.

***Dendritic Cells Vaccines**:

Dendritic cells are particular antigen-introducing safe cells, and are often used in disease immunization. To shield the body from a danger, different resistant cells, including dendritic cells, move in to send off an early assault once a microbe (like an infection or microorganisms) or cells that are acting strangely have been identified. Dendritic cells get flotsam and jetsam and proof of the danger (antigens) and convey it to the lymph hubs, where they present the proof to B cells (which discharge antibodies), and White blood cells (the heroes of the safe framework). Assuming the Immune system microorganisms or B cells perceive the proof introduced by the dendritic cells, they will start to send off areas of strength for an exceptionally unambiguous assault against the danger

***Cytokine-Induced killer Immunotherapies**:

A wide range of resistant cell types and cell change methodologies have been produced for use in disease immunotherapy, and many have been or alternately are right now being tried. For instance, cytokine-prompted executioner cell (CIK) and lymphokine-initiated executioner cell (LAK) treatments comprise of a blend of safe cells with elements of normal executioner T (NKT) cells or regular executioner (NK) cells that can target and dispose of malignant growth cells. These treatments are produced by developing blood and resistant cell-shaping hematopoietic immature microorganisms with particles (e.g., cytokines) that can prompt their turn of events and development in a research center. Cell treatments that use macrophages, invariant regular executioner cells (iNKT) cells and ɣ□T cells are additionally being investigated. Further, hereditary designing can be utilized to add or erase qualities from for all intents and purposes any insusceptible cells to improve their potential disease battling capabilities, opening up the entryway for some more cell-based immunotherapies pushing ahead

***Hematopoietic Stem Cell Transplantation**

Hematopoietic undifferentiated organism transplantation (HSCT) is the most established type of cell-based immunotherapy. Hematopoietic undifferentiated organisms are cells that basically live in bone marrow (the wipe like substance within bones) and lead to new red platelets, safe cells, and platelets that proceed to course all through the body. A hematopoietic foundational microorganism relocate includes moving sound hematopoietic undifferentiated cells to a patient to revamp their blood and resistant framework, as a rule after it has been debilitated or obliterated because of disease or forceful malignant growth treatment.

Immature microorganism transplantation has turned into a standard piece of therapy for a few tumors, particularly blood malignant growths, like high level leukemia, lymphoma, or various myeloma. These tumors dwell basically in the blood as well as bone marrow and upset resistance. They frequently require medicines that can clear out the stem, blood, and safe cells of the patient. Undifferentiated organism transplantation is additionally now and again utilized in patients with blood malignant growth who have no evident disease trouble remaining (they are disappearing), however are

at exceptionally high gamble for the disease to return (backslide).

PHARMACOKINETIC PROFILE:

A populace PK (PopPk) profile of Dostarlimab was very much portrayed by a 2-compartment model with time-subordinate direct disposal. At clinically pertinent portions, the PopPK model uncovered that Dostarlimab openness is roughly portion corresponding. The PK profile of Dostarlimab is for the most part predictable with that of other endorsed PD-1 inhibitors, Pembrolizumab, Nivolumab, and Cemiplimab on the grounds that PK boundaries were comparable, and both time-shifting CL and a direct disposal design were recently noticed for these specialists inside their helpful portion range. While Dostarlimab's time-fluctuating CL is like other PD-1 inhibitor perceptions, the commonplace most extreme drop in CL over the long run was determined at 14.9%, which is lower than that announced for Pembrolizumab (20-30%), Nivolumab (25%), or Cemiplimab (35.9%). Curiously, in stepwise covariate demonstrating, cancer type (EC (dMMR/MSI-H), NSCLC or MSI-H, and so forth.) still up in the air to be a measurably critical covariate and didn't influence Dostarlimab PK qualities. Body weight and time-shifting egg whites were seen to impact Dostarlimab PK, as recently announced for other PD-1 inhibitors.

Dostarlimab has a pharmacokinetics (PK) profile that allows the dosing span to be expanded from three to about a month and a half. The pharmacodynamic action of Dostarlimab was led in both in vitro and in vivo exploratory frameworks. 500 mg was given intravenously every three weeks during the first cycle, and the absorption was described as follows: the mean Cmax and AUC0-tau of dostarlimab as 171 mcg/mL and 35,730 mcg.h/mL, individually. When regulated at 1000 mg at regular intervals, the mean Cmax and AUC0-tau are 309 mcg/mL and 95,820 mcg.h/mL, separately. Dostarlimab has a mean volume of distribution of 5.3 L at steady state. The metabolism of Dostarlimab has not yet been characterized, but it is currently estimated to be broken down into smaller peptides and amino acids through catabolic pathway

SAFETY PROFILE:

Dostarlimab's secondary effect profile is expected to be steady with glut side effects, including possibly serious safe intervened responses. Obstruction, sickness, looseness of the bowels, sickliness, and weariness/asthenia were the most successive incidental effects (20%). Intense renal harm, urinary lot contamination, sepsis, stomach uneasiness, and pyrexia happened in 2.9% of patients getting dostarlimab, which was regulated to 34% of patients. Expanded transaminases, sepsis, bronchitis, and pneumonitis were the unfriendly impacts that caused the medication's end (five patients complete); 4.8% of patients forever quit getting treatment because of incidental effects. Extreme and lethal safe intervened impacts are conceivable whenever during or after treatment on account of utilizing dostarlimab. In the wake of getting dostarlimab treatment, 1.4% (7/515) of patients had pneumonitis, of whom 1.2% had grade 2 and 0.2% had grade 3 pneumonitis.96 Patients who have proactively gone through thoracic radiation might be more vulnerable to this unfriendly occasion. Altogether, 1.4% (7/515) of patients experienced safe intervened colitis, 0.8% with grade 2, and 0.6% with grade 3 unfriendly occasions, which were more normal in patients with safe intervened colitis impervious to corticosteroids.

Dostarlimab caused invulnerable interceded endocrinopathies, including hypothyroidism (7.2% (37/515), 1.4% adrenal inadequacy out of whom 0.8% had grade 2 and 0.6% had grade 3, thyroiditis (0.4% (2/515 patients), hypophysitis and type 1 diabetes mellitus are likewise other human safe intervened unfavorable responses of the medication.

DOSTARLIMAB WITH COMBINATION:

Dostarlimab in blend with niraparib despite everything bevacizumab or in mix with carboplatin-paclitaxel no matter what bevacizumab until illness movement, unsatisfactory harmfulness, or withdrawal from the review. Dose-limiting toxicities (DLTs), RP2Ds, pharmacokinetics and preliminary efficacy for each combination were all prespecified endpoints in all parts.

Dostarlimab, a poly (ADP-ribose polymerase inhibitor), and niraparib, a poly (ADP-ribose polymerase inhibitor), were used in this study to determine the recommended phase 2 doses (RP2Ds) and to examine the safety and efficacy of these treatments in patients with advanced cancer. Carboplatin-paclitaxel chemotherapy was used with or without bevacizumab was also evaluated.

Pembrolizumab and Dostarlimab have shown noteworthy outcomes in MMR-;lacking cases, and the relationship of pembrolizumab and Lenvatinab is turning into a norm of care for pretreated repetitive MMR-capable endometrial cancer. Further advances are expected to grasp essential and optional components of protection from immunotherapy and to execute ICI in the first-line metastatic setting and beginning phase cancers.

These medications are likewise demonstateted for dMMR/MSI-H testing. Some blend treatments, like PD-1/PD-L1 in addition to chemotherapy, radiation, angiogensis inhibitors, designated treatment, extra resistant designed spot inhibitors, co stimulatory particle agonsists, interferon quality trigger agonsists, waste microbiota transplantation, epigenetic modulators, or metabolic modulators show better reaction rates and predominant anticancer efficacies.

Pembrolizumab, Nivolumab, Cemiplimab, Atezolizumab, Avelumab and Durvalumab are monoclonal antibodies that upset the collaboration of PD-1/PD-L1 and consequently dispense with diseases capacity to sidestep the insusceptible framework.

II. CONCLUSION

Dostarlimab, the fourth PD-1 monoclonal counter acting agent, was endorsed in 2021. Driving the patients own insusceptible framework to act against the lethal sickness of disease could potentative the quick reduction of neoplastic cells. Improve the identification of patients who are most likely to benefit from dostarlimab through prospective studies. Dostarlimab is a novel medication with an activity similar to other PD-1/PD-L1 inhibitors that was previously used to treat endometrial and colorectal malignancies. Many malignancies, including as pancreatic, ovarian, fallopian tube, non-small cell lung cancer and small cell lung cancer can be treated with this medication in the future.

REFERENCES

[1] Singh V, Sheikh, Abourehab MAS, Kesharwani P. Dostarlimab as a Miracle Drug: Rising Hope against Cancer Treatment. Biosensors (Basel). 2022 Aug 8;12(8): 617. doi: 10.3390/bios 12080617. PMID: 36005013; PMCID: PMC9406030.

[2] Costa B, Vale N. Dostarlimab: A Review Biomolecules.2022 Jul 26;12(8):1031. doi:10.3390/biom12081031. PMID: 35892341; PMCID: PMC9331682.

[3] Le D.T., Durham J.N., Smith K.N., et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi: 10.1126/science.aan6733.

[4] Cercek A., Lumish M., Sinopoli J., et al. PD-1 blockade in mismatch repair deficient, locally advanced rectal cancer. N. Engl. J. Med. 2022 doi: 10.1056/NEJMoa2201445.

[5] Ganesh K., Stadker Z.K., Cercek A., et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat. Rev. Gastroenterol. Hepatol. 2019;16(6):361-375. doi: 10.1038/s41575-019-0126-x.

[6] Topalian S.L., Hodi F.S., Brahmer J.R., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012;366(26):2443-2454. doi: 10.1056/NEJMoa1200690.

[7] Ana Oaknin,MD,PhD, Anna V. Tinker,MD, Lucy Gilbert, MD; et al. Assess the antitumor activity and safety of dostarlimab with deficient mismatch repair endometrial cancer. JAMA Oncol. 2020;6(11):1766-1772. doi:10.1001/jamaoncol.2020.4515.

[8] Soerjomataram I, Bray F. Planning for tomorrow: global cancer incidence and the role of prevention 2020–2070. Nat Rev Clin Oncol 2021; 18(10): 663–672.

[9] Turashvili G, Brogi E. Tumor heterogeneity in breast cancer. Front Med 2017; 4: 227

[10] Hassanpour SH, Dehghani M. Review of cancer from perspective of molecular. J Cancer Res Pract 2017; 4(4): 127–129.

[11] Oronsky B, Gastman B, Conley AP, Reid C, Caroen S, Reid T. Oncolytic adenoviruses: the cold war against cancer finally turns hot. Cancers (Basel) 2022; 14(19): 4701.

[12] Marzoughi S, Chen T. Immune checkpoint inhibitorinduced encephalitis with dostarlimab in two patients: Case series. eNeurologicalSci 2021; 25: 100356.

[13] Rizzo A. Immune checkpoint inhibitors and mismatch repair status in advanced endometrial cancer: elective affinities. J Clin Med 2022; 11(13): 3912.

[14] Green AK, Feinberg J, Makker V. A review of immune checkpoint blockade therapy in endometrial cancer. Am Soc Clin Oncol Educ Book 2020; (40): 238–244.

[15] Takei S, Kawazoe A, Shitara K. The new era of immunotherapy in gastric cancer. cancers (Basel) 2022; 14(4): 1054.

[16] Park UB, Jeong TJ, Gu N, Lee HT, Heo YS. Molecular basis of PD-1 blockade by dostarlimab, the FDAapproved antibody for cancer immunotherapy. Biochem Biophys Res Commun 2022; 599: 31–37.

[17] Gadducci A, Cosio S. Pharmacological treatment of advanced, persistent or metastatic endometrial cancer: State of the art and perspectives of clinical research for the special issue "diagnosis and management of endometrial cancer". Cancers (Basel) 2021; 13(24): 6155.

[18] Shang J, Huang L, Huang J, Ren X, Liu Y, Feng Y. Population pharmacokinetic models of anti-PD-1 mAbs in patients with multiple tumor types: A systematic review. Front Immunol 2022; 13: 871372.

[19] Qin W, Hu L, Zhang X, Jiang S, Li J, Zhang Z, Wang X. The diverse function of PD-1/PD-L pathway beyond cancer. Front Immunol 2019; 10: 1–16.

[20] Wang X, Yang X, Zhang C, Wang Y, Cheng T, Duan L, Tong Z, Tan S, Zhang H, Saw PE, et al. Tumor cellintrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy. Proc Natl Acad Sci 2020; 117(12): 6640–6650.

[21] Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol 2018; 18(3): 153–167.

[22] Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, et al. The PD-1 expression balance between effector and regulatory T-cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol 2020; 21(11): 1346–1358.

[23] Acúrcio RC, Pozzi S, Carreira B, Pojo M, Gómez-Cebrián N, Casimiro S, Fernandes A, Barateiro A, Farricha V, Brito J, et al. Therapeutic targeting of PD-1/PD-L1 blockade by novel small-molecule inhibitors recruits cytotoxic T-cells into solid tumor microenvironment. J Immunother Cancer 2022; 10(7): 1–15.

[24] Iannantuono GM, Torino F, Rosenfeld R, Guerriero S, Carlucci M, Sganga S, Capotondi B, Riondino S, Roselli M. The role of histology-agnostic drugs in the treatment of metastatic castration-resistant prostate cancer. Int J Mol Sci 2022; 23(15): 8535.

[25] Jeong TJ, Lee HT, Gu N, Jang YJ, Choi SB, Park UB, Lee SH, Heo YS. The high-resolution structure reveals remarkable similarity in PD-1 binding of cemiplimab and dostarlimab, the FDA-approved antibodies for cancer immunotherapy. Biomed 2022; 10(12): 3154.

[26] Alkholifi FK, Alsaffar RM. Dostarlimab an inhibitor of PD1/PD-L1: A new paradigm for the treatment of cancer. Medicina (Kaunas) 2022; 58(11): 1572.

[27] Kaplon H, Chenoweth A, Crescioli S, Reichert JM. Antibodies to watch in 2022. mAbs 2022; 14(1): 2014296.

[28] Kousar K, Ahmad T, Naseer F, Kakar S, Anjum S. Immune landscape and immunotherapy options in cervical carcinoma. Cancers (Basel) 2022; 14(18): 4458.

[29] Melhem M, Hanze E, Lu S, Alskär O, Visser S, Gandhi Y. Population pharmacokinetics and exposure–response of anti-programmed cell death protein-1 monoclonal antibody dostarlimab in advanced solid tumours. Br J Clin Pharmacol 2022; 88(9): 4142-4154.

[30] Cicala CM, Musacchio L, Scambia G, Lorusso D. Dostarlimab: From preclinical investigation to drug approval and future directions. Hum Vaccin Immunother 2023; 19(1): 2178220.